Planche V, Schindler S, Knopman DS, Frisoni G, et al. The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence. Alzheimers Dement 2025;21:e70068.
PMID: 40243238